Journals / Acta Medica / 2021 / Cilt: 52 - Sayı: 3

Pediatric Liver Transplantation as Enzyme Replacement Therapy for Rare Metabolic Diseases with No Structural Liver Damage

Pages
244–250
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Especially, living donor liver transplantation is very important for populations with very low organ donation rates.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Very rare monogenic metabolic diseases without structural liver damage can be cured by liver transplantation.
📊
Key Findings & Data:The aims of this single center study of children with metabolic diseases showing structurally normal liver parenchyma were to analyze the indications and post-operative outcomes of liver transplantation, identification of developmental and metabolic benefits of the procedure with recognition of peri-operative difficulties to improve the success rate.
💡
Conclusion & Impact:Especially, living donor liver transplantation is very important for populations with very low organ donation rates.
🔬Design:Research Article
📍Scope:2015 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Very rare monogenic metabolic diseases without structural liver damage can be cured by liver transplantation. This process is a surgical enzyme replacement therapy, and defective enzymes may or may not be confined to the liver. The aims of this single center study of children with metabolic diseases showing structurally normal liver parenchyma were to analyze the indications and post-operative outcomes of liver transplantation, identification of developmental and metabolic benefits of the procedure with recognition of peri-operative difficulties to improve the success rate. Materials and Methods: Patients under the age of 19-year-old who underwent liver transplantation for metabolic disorders with no structural liver injury between January 2015 and June 2021 analyzed retrospectively. Patient and graft survivals, indications for transplantation, presence of extra-hepatic enzyme deficiency causing other organ damage, inclusion of simultaneous or sequential kidney transplantation, immunosuppressive protocols, post-transplant complications, and metabolic outcomes were identified. Results: Eight children with primary hyperoxaluria type 1 (n = 4), Maple syrup urine disease (n = 1), Crigler-Najjar syndrome type 1 (n=1), familial hypercholesterolemia (n=1) and propionic acidemia (n = 1) received left lobe (n=6) and left lateral segment (2) allografts from living donors. The median age of 4 girls and 4 boys at time of transplantation was 6.8 years (range 2.2-12.7 years). The median follow-up time was 3.3 years (range 1.5-5.7 years). The most common post-transplant complications were biliary system complications and infections and, two patients died because of sepsis. Six patients are alive with normal functioning allografts and metabolically stable on unrestricted diet. Conclusion: Liver transplantation is a lifesaving treatment and improves patient’s and parent’s life quality for metabolic disorders with no parenchymal injury despite strict dietary restrictions and medical therapies. Especially, living donor liver transplantation is very important for populations with very low organ donation rates.

🔖

Cite This Article

ÇELİK, N., EMİROĞLU, R. (2022). Pediatric Liver Transplantation as Enzyme Replacement Therapy for Rare Metabolic Diseases with No Structural Liver Damage. Acta Medica, Cilt: 52 - Sayı: 3, 244–250. https://ajindex.com/articles/427532

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Darwish AA, McKiernan P, Chardot C. Paediatric liver transplantation for metabolic disorders. Part 1: Liverbased metabolic disorders without liver lesions. Clin Res Hepatol Gastroenterol 2011; 35(3): 194-203
  2. Mazariegos G, Shneider B, Burton B, et al. Liver transplantation for pediatric metabolic disease. Mol Genet Metab 2014; 111(4): 418-27
  3. Hansen K, Horslen S, Metabolic liver disease in children. Liver Transpl 2008; 14: 713–733
  4. Kayler LK, Merion RM, Lee S et al, Long-term survival after liver transplantation in children with metabolic disorders. Pediatr Transplant 2002; 6: 295–300
  5. Kayler LK, Rasmussen CS, Dykstra DM et al, Liver transplantation in children with metabolic disorders in the United States. Am J Transplant 2003; 3: 334-339
  6. Stevenson T, Millan MT, Wayman K et al. Long-term outcome following pediatric liver transplantation for metabolic disorders. Pediatr Transplant 2010; 14: 268–275
  7. Sokal EM, Sokol R, Cormier V et al, Liver transplantation in mitochondrial respiratory chain disorders. Eur J Pediatr 158 (Suppl. 2) 1999: 81–84
  8. McKiernan PJ, Ganoza A, Squires JE et al. Evolving Trends in Liver Transplant for Metabolic Liver Disease in the United States. Liver Transpl 2019; 25(6): 911-921
  9. Hadžić N. Metabolic Indications for Pediatric Liver Transplantation: A Slow Train Coming. Liver Transpl 2019; 25(6): 829-830
  10. Kwong A, Kim WR, Lake JR et al. OPTN/SRTR 2018 Annual Data Report: Liver. Am J Transplant 2020; 20 Suppl s1: 193- 299
  11. Kasahara M, Sakamoto S, Fukuda A. Pediatric living-donor liver transplantation. Semin Pediatr Surg 2017; 26(4): 224- 232
  12. Hong SK, Yi NJ, Yoon KC et al. Outcomes of Pediatric Liver Transplantation in Korea Using Two National Registries. J Clin Med 2020; 9(11): 3435
  13. Cochat P, Liutkus A, Fargue S, et al. Primary hyperoxaluria type 1: still challenging! Pediatr Nephrol 2006; 21(8): 1075- 81
  14. Fargue S, Harambat J, Gagnadoux MF et al. Effect of conservative treatment on the renal outcome of children with primary hyperoxaluria type 1. Kidney Int 2009; 76(7): 767-73
  15. Cibrik DM, Kaplan B, Arndorfer JA et al. Renal allograft survival in patients with oxalosis. Transplantation 2002; 74(5): 707-10
  16. McDonald JC, Landreneau MD, Rohr MS et al. Reversal by liver transplantation of the complications of primary hyperoxaluria as well as the metabolic defect. N Engl J Med 1989; 321(16): 1100-3
  17. Perera MT, McKiernan PJ, Sharif K et al. Renal function recovery